EyePoint (EYPT) Non-Current Deffered Revenue (2011 - 2024)
EyePoint (EYPT) posted Non-Current Deffered Revenue of $10.9 million for Q4 2024, down 3.39% sequentially from $11.2 million in Q3 2024, and down 47.55% YoY from $20.7 million in Q1 2024.
Analysis
EyePoint (EYPT) Non-Current Deffered Revenue (2011 - 2024) Analysis & Trends
EyePoint has reported Non-Current Deffered Revenue for 12 years, with the latest figure at $10.9 million in Q4 2024.
- Quarterly Non-Current Deffered Revenue fell 47.55% year-over-year to $10.9 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $10.9 million (down 47.55% YoY) and the FY2024 annual result came in at $10.9 million, down 47.55% from the prior year.
- Non-Current Deffered Revenue retreated to $10.9 million in Q4 2024 per EYPT's latest filing, from $11.2 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $44.0 million in Q2 2023 and troughed at $10.9 million in Q4 2024.
- A 5-year average of $16.9 million and a median of $14.3 million in 2022 frame the typical range for Non-Current Deffered Revenue.
- The sharpest annual moves came in 2023 and 2024: Non-Current Deffered Revenue surged 212.87% in 2023, then sank 73.47% in 2024.
- Over 5 years, Non-Current Deffered Revenue stood at $15.6 million in 2020, then fell by 6.76% to $14.6 million in 2021, then dropped by 6.89% to $13.6 million in 2022, then soared by 52.63% to $20.7 million in 2023, then sank by 47.55% to $10.9 million in 2024.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $10.9 million, $11.2 million, and $11.7 million for Q4 2024, Q3 2024, and Q2 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 10.85 Mn |
| Sep 30, 2024 | 11.23 Mn |
| Jun 30, 2024 | 11.68 Mn |
| Mar 31, 2024 | 12.11 Mn |
| Dec 31, 2023 | 20.69 Mn |
| Sep 30, 2023 | 32.34 Mn |
| Jun 30, 2023 | 44.02 Mn |
| Mar 31, 2023 | 13.27 Mn |
| Dec 31, 2022 | 13.56 Mn |
| Sep 30, 2022 | 13.80 Mn |
| Jun 30, 2022 | 14.07 Mn |
| Mar 31, 2022 | 14.30 Mn |
| Dec 31, 2021 | 14.56 Mn |
| Sep 30, 2021 | 14.79 Mn |
| Jun 30, 2021 | 15.13 Mn |
| Mar 31, 2021 | 15.35 Mn |
| Dec 31, 2020 | 15.62 Mn |
| Dec 31, 2017 | 42,000.00 |
| Sep 30, 2017 | 47,000.00 |
| Jun 30, 2017 | 51,000.00 |